FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergi

– Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placebo –– More than 40% o...

Related Keywords

California ,United States ,South San Francisco ,Stanford School ,America ,American ,Levi Garraway ,Lindsey Mathias ,Loren Kalm ,Kenneth Mendez ,Bruno Eschli ,Julie Burns ,Stanford School Of Medicine ,Allergy Foundation Of America ,American Academy Of Allergy ,Drug Administration ,Roche Group ,Global Product Development ,Food Allergy Research ,Genentech ,Consortium For Food Allergy Research Co ,National Institutes Of Health ,Novartis Pharmaceuticals Corporation ,Johns Hopkins Children Center ,National Institute Of Allergy ,Global Product ,National Institute ,Infectious Diseases ,National Institutes ,Johns Hopkins Children ,Annual Meeting ,Sung Poblete ,Allergy Foundation ,Adjunct Therapy ,Food Allergic Children ,Novartis Pharmaceuticals ,Important Safety ,Prescribing Information ,Medication Guide ,Important Safety Information ,